News
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...
As per the petition, GLP-1-RA drugs were originally developed and internationally ... and absence of a robust pharmacovigilance or regulatory oversight mechanism. It said that there is no evidence to ...
The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like ...
Theratechnologies entered a definitive agreement to be acquired by Future Pak. Find out why do not expect to see THTX stock ...
In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, ...
Research indicates GLP-1 receptor agonists, like Ozempic, may elevate testosterone levels in men while promoting weight loss. A study presented at ENDO 2025 showed a significant increase in ...
After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...
The PIL seeks a ban on the marketing and distribution of specific GLP-1 receptor agonist (RA) drugs, namely Semaglutide, ...
GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...
For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs), according to a study published online July 9 in ...
Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.
As she awaited a heart ablation to treat her AFib, Dolores Catania turned to food for comfort. After her procedure, she ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results